7-(4-甲氧基苯基)-7-恶庚烷 | 21244-11-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 7-(4-甲氧基苯基)-7-恶庚烷
• 英文名称: 7-(4-methoxy-phenyl)-7-oxo-heptanoic acid
• 英文别名: 7-(4-Methoxy-phenyl)-7-oxo-heptansaeure；7-(4-methoxyphenyl)-7-oxoheptanoic acid
• CAS: 21244-11-1
• 化学式: C₁₄H₁₈O₄
• mdl: MFCD01311627
• 分子量: 250.295
• InChiKey: CEWMUHNHATTXSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  7-(4-甲氧基苯基)-7-恶庚烷 在 Ru-carbon 盐酸 、 氯化亚砜 、 氢溴酸 、 氢气 、 双氧水 、 对甲苯磺酸 作用下， 以 吡啶 、 甲醇 、 乙醚 、 乙醇 、 水 、 溶剂黄146 为溶剂， 25.0~104.0 ℃ 、11.28 MPa 条件下， 反应 10.5h， 生成 trans-6-<6-(4-hydroxycyclohexyl)hexyl>-2,3-dimethoxy-5-methyl-1,4-benzoquinone
  参考文献：
  名称：

  Synthesis, metabolism, and in Vitro biological activities of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (CV-2619)-related compounds.

  摘要：

  合成了 6（10-羟基癸基）-2，3-二甲氧基-5-甲基-1，4-苯醌（1，CV-2619）的二甲基衍生物（3a 和 3b）、代谢物 2-4 的二甲基衍生物（4），以及 1 的羟基烷基链发生改变的化合物（13、20、21、23a 和 23b），用于代谢研究和生物活性评估。除去甲基衍生物（3a、3b 和 4）外，这些化合物在琥珀酸氧化系统中显示出与 1 相当的电子转移效应。化合物 13 和 23b 可抑制大鼠肝匀浆的脂质过氧化反应。

  DOI：

  10.1248/cpb.36.178
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下， 生成 7-(4-甲氧基苯基)-7-恶庚烷
  参考文献：
  名称：

  不对称β-二酮的碱性裂解；酰基环己酮的开环形成ε-酰基己酸。

  摘要：

  DOI：

  10.1021/ja01192a016

文献信息

• Organic materials with nonlinear optical properties
  申请人：The Board of Trustees of the Univ. of Illinois

  公开号：US05412144A1

  公开（公告）日：1995-05-02

  The present invention is directed to organic materials that have the ability to double or triple the frequency of light that is directed through the materials. Particularly, the present invention is directed to the compound 4-[4-(2R)-2-cyano-7-(4'-pentyloxy-4-biphenylcarbonyloxy)phenylheptylidene) phenylcarbonyloxy]benzaldehyde, which can double the frequency of light that is directed through the compound. The invention is also directed to the compound (12-hydroxy-5,7-dodecadiynyl) 4'-[(4'-pentyloxy-4-biphenyl)carbonyloxy]-4-biphenylcarboxylate, and its polymeric form. The polymeric form can triple the frequency of light directed through it.

  本发明涉及具有通过材料传导的光频率加倍或加倍的有机材料。特别地，本发明涉及化合物4-[4-(2R)-2-氰基-7-(4'-戊氧基-4-联苯基羰氧基)苯基庚烯基)苯基羰氧基]苯甲醛，该化合物可以将通过该化合物传导的光频率加倍。该发明还涉及化合物(12-羟基-5,7-十二炔基)4'-[(4'-戊氧基-4-联苯基)羰氧基]-4-联苯基羧酸酯及其聚合形式。聚合形式可以将通过它传导的光频率加倍。
• TBD-Catalyzed Direct 5- and 6-<i>enolexo</i>Aldolization of Ketoaldehydes
  作者：Cynthia Ghobril、Cyrille Sabot、Charles Mioskowski、Rachid Baati

  DOI：10.1002/ejoc.200800539

  日期：2008.8

  Treatment of unfunctionalized acyclic ketoaldehydes with a catalytic amount of 1,5,7-triazabicyclo[4.4.0]dec-5-ene induces a direct intramolecular 5- and 6-enolexo aldolization, furnishing 2-ketocyclopentanols and 2-ketocyclohexanols in good-to-excellent yields. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)

  用催化量的 1,5,7-三氮杂双环 [4.4.0]dec-5-ene 处理未官能化的无环酮醛诱导直接的分子内 5-和 6-烯醇醛醇缩合，提供 2-酮环戊醇和 2-酮环己醇到优秀的产量。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
• 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  申请人：Siegel Craig

  公开号：US20100256216A1

  公开（公告）日：2010-10-07

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式（I）表示，或其药学上可接受的盐。一种药物组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。一种治疗需要的受试者的方法包括向受试者施用结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。该受试者患有2型糖尿病；与糖尿病性肾病相关的肾肥大或增生；Tay-Sachs病；高氏病；或Fabry病。分别降低受试者血浆TNF-α、降低血糖水平、降低糖化血红蛋白水平、抑制葡糖鞘氨醇合成酶和降低糖脂浓度的方法包括向受试者施用结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。
• GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE
  申请人：Genzyme Corporation

  公开号：US20130225573A1

  公开（公告）日：2013-08-29

  A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

  一种治疗肾小球疾病的方法，所述肾小球疾病选自系列包括系膜增生性肾小球肾炎、崩解性肾小球病、增生性狼疮性肾炎、新月体性肾小球肾炎和膜性肾病，该方法包括向受试者施用有效量的葡糖鞘氨醇合成酶抑制剂。
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Genzyme Corporation

  公开号：US20150225393A1

  公开（公告）日：2015-08-13

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式(I)表示，或其药学上可接受的盐。一种制药组合物包括一种由结构式(I)表示的化合物或其药学上可接受的盐。一种治疗需要的受体的方法包括向受体施用由结构式(I)表示的化合物或其药学上可接受的盐的治疗有效量。该受体患有2型糖尿病；与糖尿病性肾病相关的肾肥大或增生；Tay-Sachs病；Gaucher病；或Fabry病。分别降低患者血浆TNF-α、降低血糖水平、降低糖化血红蛋白水平、抑制葡萄糖酰胺合成酶和降低糖脂质浓度的方法包括向需要的受体施用由结构式(I)表示的化合物或其药学上可接受的盐的治疗有效量。